AI vs Traditional Literature Review: What Changes, What Doesn't

1. Scoping the research question — augmented

Traditional approach: read a few review papers, consult a supervisor, iterate on keywords over days.

With AI in 2026: an AI research assistant can surface the landscape of a biomedical field in minutes — named entities, main subfields, most-cited papers, emerging research clusters. Tools like BioSkepsis's knowledge graph, Elicit's summary view, and Consensus's topic cards compress the "what does this field look like?" phase from days to an afternoon. BioSkepsis retrieval is weighted by Gene Ontology terms and MeSH descriptors, so the landscape returned for a query about TIL density and immunotherapy response in TNBC reflects the biological concept structure — not just text frequency.

What does not change: the question still has to be sharp. AI tools reward precise PICO-style questions and produce noise from vague ones. A vague question produces a vague landscape. Garbage in, garbage out is unchanged.

2. Searching the biomedical literature — partly replaced

Traditional approach: MeSH lookup, Boolean string construction, run across 2–3 databases, iterate on the string.

With AI in 2026: retrieval-augmented tools let you pose natural-language questions and return ranked papers with rationale. For scoping reviews and clinical-question lookups, AI search is strictly faster than Boolean construction. Semantic search catches papers that keyword search misses — synonyms, variant phrasings, cross-disciplinary matches — particularly valuable for emerging topics where MeSH terms lag behind the literature by 12–18 months.

What does not change: systematic reviews require a reproducible, documented Boolean search string in at least two databases. AI-generated result lists are opaque and non-reproducible by design — running the same natural-language query twice does not guarantee the same ranked output. PRISMA 2020 is explicit that the search strategy must be fully reported; AI tools can supplement but not replace the formal search for a PRISMA-compliant systematic review.

3. Title and abstract screening — augmented with caveats

Traditional approach: two reviewers independently screen titles and abstracts, resolve disagreements, then full-text screen included records.

With AI in 2026: tools like Rayyan, ASReview, and DistillerSR use active learning to prioritise papers for human review, cutting screening time by 30–70% in published comparisons. Elicit's screening mode and BioSkepsis's smart-select apply similar ranking to in-scope candidates, surfacing the most likely includes first so reviewers reach the boundary of inclusion faster.

What does not change: the human-in-the-loop requirement. Cochrane guidance and most high-impact journals still require dual human screening for included studies in a systematic review. AI can triage and prioritise, but a human signs off on every inclusion decision. Reviewers will ask about your AI-assisted screening workflow — be prepared to report it transparently in the methods section.

4. Data extraction — partly replaced

Traditional approach: build a bespoke extraction form, two reviewers extract independently, reconcile disagreements field by field.

With AI in 2026: Elicit's column-extraction workflow lets you define fields in plain English — sample size, intervention dose, primary endpoint, effect size, allocation concealment — and auto-extract across dozens or hundreds of papers into a comparison grid. BioSkepsis's mechanistic-links table performs a similar function for biological pathway relationships, pulling mechanism claims from full text including methods and supplementary data. Extraction accuracy has improved substantially in the last 18 months but is not publication-ready without verification.

What does not change: a human must verify every extracted field against the source passage. Automated extraction is a draft, not a final table. For regulated submissions to HTA bodies or regulators, a fully human-verified extraction with documented reconciliation is still required. Using AI-extracted values in a meta-analysis without per-field verification is a methodological error.

5. Evidence synthesis — augmented

Traditional approach: thematic grouping, narrative synthesis, meta-analysis where quantitative comparison across studies is valid.

With AI in 2026: AI tools generate quick synthesis drafts, identify contradictions between studies (Scite is purpose-built for citation context — supporting, contradicting, or mentioning), and summarise findings across thematic groupings. BioSkepsis's full-text reasoning can flag where differences in methods, controls, or model systems explain conflicting results — a capability that requires reading beyond the abstract and is missed by tools that process only abstract text.

What does not change: expert judgement about which studies are genuinely comparable, which outcomes are clinically or biologically meaningful, and how to weight heterogeneous evidence. AI-generated synthesis is a first draft. The interpretation — particularly the clinical applicability and mechanistic interpretation — remains human work that cannot be outsourced to a generative model.

6. Quality assessment — mostly unchanged

Traditional approach: apply the appropriate instrument — Cochrane RoB 2, ROBINS-I, GRADE, QUADAS-2, or another discipline-validated tool — with dual-reviewer completion and documented justification for each domain.

With AI in 2026: some tools offer preliminary bias flagging — selection bias from non-random allocation, incomplete blinding reporting, attrition rate warnings — that can orient a reviewer before formal assessment. No tool currently produces a GRADE evidence profile or a Cochrane RoB 2 rating that a competent methodologist would accept without independent verification. Quality assessment stays human for all publication-grade work.

7. Reporting and PRISMA compliance — mostly unchanged

Traditional approach: PRISMA flow diagram, PROSPERO registration before data collection, full search strategy in the appendix, PRISMA checklist submitted with the manuscript.

With AI in 2026: tools can generate first-draft PRISMA flow diagram text and help populate checklist items, but the standards themselves have not changed. Reporting requirements have become stricter, not looser — ICMJE, Cochrane, and EASE have all issued guidance since 2023 requiring explicit declaration of AI tool use in the methods section, including which tools were used, for which tasks, and how outputs were verified.

What AI cannot do in biomedical literature review in 2026

Common mistakes when using AI for biomedical literature review

Tools and resources for AI-assisted biomedical literature review

Where BioSkepsis fits in the biomedical review pipeline

BioSkepsis fits into the augmented, not replaced, phases of the pipeline. Its biology-native knowledge graph surfaces biologically relevant papers during scoping — weighted by Gene Ontology terms and MeSH descriptors, not just text frequency. Full-text reasoning extracts methods-level and supplementary details during data extraction, catching caveats that abstract-only tools miss. Mechanistic-links tables speed synthesis for pathway and mechanism-of-action questions.

Because retrieval is grounded in peer-reviewed sources and the tool declines to answer when evidence is insufficient rather than generating a plausible-sounding response, it reduces the hallucination risk that makes teams cautious about AI in publication workflows. The formal PubMed Boolean search still runs. Extracted fields are still verified. BioSkepsis shortens the iteration time between those steps and surfaces biological context that keyword search alone would not find.

Frequently asked questions